Dashboard
Manage Tickers

INMBInmune Bio, Inc.

Nasdaq inmunebio.com


$ 11.20 $ 0.35 (3.23 %)    

Monday, 20-May-2024 15:59:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ 2.02 (0.45 %)
DIA $ 398.57 $ -1.85 (-0.46 %)
SPY $ 530.36 $ 0.23 (0.04 %)
TLT $ 91.26 $ -0.27 (-0.3 %)
GLD $ 225.37 $ 0.90 (0.4 %)
$ 11.23
$ 10.66
$ 0.00 x 0
$ 11.25 x 100
$ 10.66 - $ 11.23
$ 6.50 - $ 14.74
84,727
na
214.64M
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 03-02-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-03-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 03-04-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-11-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-29-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

inmune-bio-q1-2024-gaap-eps-061-misses-054-estimate-sales-14000k-miss-30000k-estimate
INmune Bio Q1 2024 GAAP EPS $(0.61) Misses...
05/09/2024 20:57:49

INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) ...

inmune-bio-provides-update-on-two-patients-from-phase-1b-alzheimers-disease-trial-receiving-xpro-under-compassionate-use-says-reports-from-the-primary-care-physicians-indicate-that-xpro-has-been-well-tolerated-throughout-the-treatment-period-with-stable-cognitive-function-observed-in-the-patients
INmune Bio Provides Update On Two Patients...
04/30/2024 12:06:11

inmune-bio-completes-first-cohort-and-initiates-second-cohort-of-phase-12-study-of-inkmune-natural-killer-cell-therapy-in-patients-with-metastatic-castration-resistant-prostate-cancer
INmune Bio Completes First Cohort And Init...
04/29/2024 12:08:52

inmune-bio-says-remains-on-track-in-line-with-prior-guidance-to-complete-its-phase-2-clinical-trial-involving-the-use-of-xpro-for-the-treatment-of-alzheimers-disease-in-patients-with-biomarkers-of-neuroinflammation
INmune Bio Says Remains On Track In Line W...
04/25/2024 20:56:19

inmune-bio-announces-97m-registered-direct-offering-of-986000-shares-and-warrants-at-984share-and-accompanying-warrant
INmune Bio Announces $9.7M Registered Dire...
04/25/2024 13:01:22

inmune-bio-announces-24-month-stability-validation-of-xpro-for-phase-iii-readiness-and-commercial-supply-chain-modeling--development-of-novel-immunogenicity-assay
INmune Bio Announces 24-Month Stability Va...
04/23/2024 12:05:06

inmune-bio-inc-raises-48m-in-gross-proceeds-through-registered-direct-offering-with-officers-employees-and-directors-purchasing-20-of-the-offering
INmune Bio Inc. Raises ~$4.8M In Gross Pro...
04/22/2024 12:06:21

INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments th...

inmune-bio-inc-presents-data-on-inb03s-role-as-an-immune-check-point-modulator-in-the-treatment-of-high-risk-breast-cancer-at-aacr-2024
INmune Bio Inc. Presents Data On INB03's R...
04/08/2024 12:16:18

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in Hi...

inmune-bio-q4-earnings-insights
INmune Bio: Q4 Earnings Insights
03/28/2024 20:20:06

inmune-bio-q4-eps-047-misses-044-estimate-sales-2800k-miss-4000k-estimate
INmune Bio Q4 EPS $(0.47) Misses $(0.44) E...
03/28/2024 20:20:01

INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.44) ...

earnings-scheduled-for-march-28-2024
Earnings Scheduled For March 28, 2024
03/28/2024 09:24:44

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

a-preview-of-inmune-bios-earnings
A Preview Of INmune Bio's Earnings
03/27/2024 18:01:18

inmune-bio-reports-significant-eeg-improvement-in-alzheimers-patients-treated-with-xpro
INmune Bio Reports Significant EEG Improve...
03/05/2024 13:02:32

Patients with Alzheimer's Disease show improvement in brainwaves following 4 weeks of XPro™ therapy.Boca Raton, Florida, Ma...

inmune-bio-announces-fda-removal-of-clinical-hold-for-alzheimers-disease-program
INmune Bio Announces FDA Removal Of Clinic...
01/30/2024 13:04:31

Core News & Articles
On Jan 16, Elevai Labs Inc Entered Into A ...
01/22/2024 17:09:10

- SEC Filing On January 16, 2023, Elevai Labs, Inc., a Delaware corporation (the "Company"), entered into a License Agr...

why-elevai-labs-stock-is-trading-higher
Why Elevai Labs Stock Is Trading Higher
01/16/2024 17:41:06

Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide...

Core News & Articles
ELEVAI Labs Signs Exclusive Worldwide Manu...
01/16/2024 13:40:42

inmune-bio-dosed-the-first-patient-in-the-phase-12-trial-of-inkmune-in-men-with-metastatic-castration-resistant-prostate-cancer
INmune Bio Dosed The First Patient In The ...
01/02/2024 13:05:52

INKmune is a biologic therapy given as out-patient therapy without the need for pre-medication or cytokine support.

inmune-bio-on-track-to-complete-enrollment-of-phase-ii-clinical-trial-in-patients-with-early-alzheimers-disease-and-biomarkers-of-inflammation-in-2024-fda-said-us-phase-ii-trial-remains-on-full-clinical-hold-pending-additional-information-request
INmune Bio On Track To Complete Enrollment...
12/18/2023 21:04:37

Enrollment in the Company's Phase II study using XProTM to treat patients with Alzheimer's Disease with neuroinflammati...

inmune-bio-inc-demonstrates-that-inb03-enhances-the-uptake-of-trastuzumab-deruxtecan-in-her2-breast-cancer-with-muc4-expression-in-poster-presented-at-san-antonio-breast-cancer-symposium
INmune Bio Inc. Demonstrates that INB03 En...
11/29/2023 13:03:41

INmune Bio, Inc. (NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments th...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION